Get the Stockscreener App
1.715
3.96%
-0.085
Brainstorm Cell Therapeutics Inc stock is traded at $1.715, with a volume of 33,789.
It is down -3.96% in the last 24 hours and down -25.81% over the past month.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
See More
Previous Close:
$1.80
Open:
$1.81
24h Volume:
33,789
Relative Volume:
0.69
Market Cap:
$9.45M
Revenue:
-
Net Income/Loss:
$-16.63M
P/E Ratio:
-2.9068
EPS:
-0.59
Net Cash Flow:
$-21.84M
1W Performance:
-12.69%
1M Performance:
-25.81%
6M Performance:
-69.67%
1Y Performance:
-32.60%
1-Day Range:
$1.71
$1.86
1-Week Range:
$1.71
$2.00
52-Week Range:
$1.71
$11.89
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Name
Brainstorm Cell Therapeutics Inc
Sector
Industry
Phone
201-488-0460
Address
1325 AVENUE OF AMERICAS, NEW YORK, NY
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-21 | Upgrade | Maxim Group | Hold → Buy |
| Nov-17-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-19-16 | Reiterated | Maxim Group | Buy |
| Dec-22-15 | Reiterated | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News
BrainStorm regains Nasdaq compliance with bid price rule By Investing.com - Investing.com South Africa
BrainStorm regains Nasdaq compliance with bid price rule - Investing.com India
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - StockTitan
Neuromuscular Disease Therapeutics Market Statistical - openPR
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - Nasdaq
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update - MarketBeat
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Amyotrophic Lateral Sclerosis (ALS) Market: Detailed Analysis - openPR
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmBCLI - AsiaOne
Stem Cell Therapy Market Projected to Reach $831.9 Million By 2032 - 대구포스트
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 91.1% - MarketBeat
Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Report By Type, Application and Geography - Elektrotransports.lv
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - MarketBeat
BCLIBrainstorm Cell Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - StockTitan
Gene and Cell Therapies for CNS Disorders Market to Experience - openPR
Brainstorm cell therapeutics CEO acquires $11,308 in stock By Investing.com - Investing.com Canada
Brainstorm cell therapeutics CEO acquires $11,308 in stock - Investing.com
Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials - TipRanks
Brainstorm Cell Therapeutics, Inc. (BCLI) requires closer examination - US Post News
5 Best Stem Cell Companies to Invest In (November 2024) - Securities.io
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com - Defense World
Market Momentum: Brainstorm Cell Therapeutics, Inc. (BCLI) Registers a -12.57 Decrease, Closing at 0.22 - The Dwinnex
Brainstorm Cell Therapeutics, Inc. (BCLI) Stock: A Year of Market Fluctuations - The InvestChronicle
The Potential Rise in the Price of Brainstorm Cell Therapeutics, Inc. (BCLI) following insiders activity - Knox Daily
Cell Therapy Technologies Market Size, Product Trends, Key Drivers, Share Analysis And Forecast To 2033 - WhaTech
Brainstorm Cell Therapeutics Stock Scheduled to Reverse Split on Tuesday, October 1st (NASDAQ:BCLI) - Defense World
Cell Theraputics Industry Analysis by Regions, Types and Application - Elektrotransports.lv
BrainStorm announces reverse stock split - Investing.com
Stem Cell Therapy Market Growth, Size, Research Report and Forecast (2024-2034) - 대구포스트
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - PR Newswire
Global Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR GrowthGlobal Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR Growth - 대구포스트
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - Defense World
Cell Theraputics Market 2024-2032 Analysis - Economica
Balance Sheet Insights: Brainstorm Cell Therapeutics, Inc. (BCLI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
BCLI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics expands stock incentive plans - Investing.com India
Brainstorm Cell Therapeutics expands stock incentive plans By Investing.com - Investing.com Canada
Brainstorm Cell Therapeutics Enacts Key Corporate Changes - TipRanks
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives New Coverage from Analysts at StockNews.com - Defense World
Global Stem Cell Therapy Market Technology, Dimension, Vertical, and Regional Insights 2024-2032 - 대구포스트
Gene and Cell Therapies Targeting CNS Disorders Market Growth - openPR
Zacks Small Cap Analysts Reduce Earnings Estimates for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Announces Earnings Results, Hits Expectations - Defense World
Thinking about buying stock in Brainstorm Cell Therapeutics, Cle - GuruFocus.com
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2024 Earnings Call Transcript - Insider Monkey
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Longview News-Journal
Earnings call: Brainstorm Cell Therapeutics outlines Phase 3b trial plans By Investing.com - Investing.com Canada
Earnings call: Brainstorm Cell Therapeutics outlines Phase 3b trial plans - Investing.com
Brainstorm Cell Therapeutics Inc Stock (BCLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Brainstorm Cell Therapeutics Inc Stock (BCLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
| Dagher Ibrahim B. | Chief Medical Officer |
Jul 19 '24 |
Sale |
0.35 |
63,000 |
22,069 |
0 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):